Biovica initiates a collaboration with Mayo Clinic to study DiviTum[®] for the on-treatment monitoring of metastatic breast cancer patients receiving CDK 4/6 inhibitors
Biovica and Mayo Clinic have entered into an agreement to study the clinical benefit of using DiviTum[®] as a blood-based test, monitoring the tumor response to therapy in patients with metastatic breast cancer.
The main purpose of including DiviTum®in studies performed at Mayo Clinic is to evaluate the changes in serum thymidine kinase activity, measured by DiviTum®, in patients with hormone positive metastatic breast cancer treated with today’s standard regimens – including CDK 4/6 inhibitors. DiviTum® measurements at the start of therapy and during treatment will be correlated to patient outcome focusing on the use of DiviTum® as a tool for easy and early evaluation of tumor progression and overall patient survival.
"We are very pleased to collaborate with Mayo Clinic in our ambition to further strengthen our already solid documentation of the value DiviTum® can bring to patients being treated for metastatic breast cancer. This collaboration complements our previous studies in this field and will be important in our market introduction of DiviTum® as a tool for the monitoring of patient response to treatments within metastatic breast cancer”says Anders Rylander, CEO Biovica.
About DiviTum® DiviTum® is an innovative biomarker assay developed with the aim to predict outcome and monitor treatment response in cancer therapy. The test measures the activity of the enzyme thymidine kinase-1 (TK) in a blood sample. In normal cells, TK activity is hardly detectable, but in proliferating cells, the levels increase. Since the degree of TK activity is highly associated with the rate of cell proliferation, it is a particularly suitable biomarker for measuring tumor aggressiveness. DiviTum® has in several trials already successfully demonstrated clinical potential in evaluating and monitoring the efficacy of endocrine standard treatments for women with metastatic breast cancer. By providing key information for early identification of those patients not responding or resistant to their on-going treatment, DiviTum® presents a non-invasive and efficacious approach to monitoring and predicting responses to standard endocrine therapies.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
This cookie is installed by Google Analytics.
A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
Hotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
Hotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.